Literature DB >> 12692010

Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome.

Jean-Pierre Després, Isabelle Lemieux, Agnès Pascot, Natalie Alméras, Martine Dumont, André Nadeau, Jean Bergeron, Denis Prud'homme.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12692010     DOI： 10.1161/01.ATV.0000062990.62034.64

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN： 1079-5642            Impact factor:   8.311


× No keyword cloud information.
  13 in total

1.  Only C-reactive protein, but not TNF-α or IL6, reflects the improvement in inflammation after bariatric surgery.

Authors:  Eva Pardina; Roser Ferrer; Juan Antonio Baena-Fustegueras; Joaquín Rivero; Albert Lecube; Jose Manuel Fort; Víctor Vargas; Roberto Catalán; Julia Peinado-Onsurbe
Journal:  Obes Surg       Date:  2012-01       Impact factor: 4.129

Review 2.  Pleiotropic effects of fibrates.

Authors:  Giulia Chinetti-Gbaguidi; Jean Charles Fruchart; Bart Staels
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

3.  Association of common C-reactive protein (CRP) gene polymorphisms with baseline plasma CRP levels and fenofibrate response: the GOLDN study.

Authors:  Jian Shen; Donna K Arnett; Laurence D Parnell; James M Peacock; Chao-Qiang Lai; James E Hixson; Michael Y Tsai; Michael A Province; Robert J Straka; Jose M Ordovas
Journal:  Diabetes Care       Date:  2008-02-19       Impact factor: 19.112

Review 4.  Role of fibric acid derivatives in the management of risk factors for coronary heart disease.

Authors:  Jean-Pierre Després; Isabelle Lemieux; Sander J Robins
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 5.  The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy.

Authors:  Sergio Fazio; MacRae F Linton
Journal:  Curr Atheroscler Rep       Date:  2004-03       Impact factor: 5.113

Review 6.  Novel markers of peripheral arterial disease.

Authors:  Farhan J Khawaja; Iftikhar J Kullo
Journal:  Vasc Med       Date:  2009-11       Impact factor: 3.239

7.  Peroxisome proliferator-activated receptor alpha (PPAR alpha) down-regulation in cystic fibrosis lymphocytes.

Authors:  Veerle Reynders; Stefan Loitsch; Constanze Steinhauer; Thomas Wagner; Dieter Steinhilber; Joachim Bargon
Journal:  Respir Res       Date:  2006-07-30

8.  Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk?

Authors:  Ahmad Aljada; Kshitij Ashwin Shah; Shaker A Mousa
Journal:  PPAR Res       Date:  2009-08-19       Impact factor: 4.964

9.  Gemfibrozil and its combination with metformin on pleiotropic effect on IL-10 and adiponectin and anti-atherogenic treatment in insulin resistant type 2 diabetes mellitus rats.

Authors:  Ashish Kumar Sharma; Sachin Kumar Raikwar; Muneem Kumar Kurmi; Bharthu Parthsarthi Srinivasan
Journal:  Inflammopharmacology       Date:  2012-10-31       Impact factor: 4.473

10.  Peroxisome Proliferator-Activated Receptor-α Agonism With Fenofibrate Does Not Suppress Inflammatory Responses to Evoked Endotoxemia.

Authors:  Claire K Mulvey; Jane F Ferguson; Jennifer Tabita-Martinez; Stephanie Kong; Rhia Y Shah; Parth N Patel; Stephen R Master; M Haris U Usman; Kathleen J Propert; Rachana Shah; Nehal N Mehta; Muredach P Reilly
Journal:  J Am Heart Assoc       Date:  2012-08-24       Impact factor: 5.501
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.